AI Signal & Stock Analysis · Strong ↑
As of Aug 14 2026, 1:04 PM, AkshayaAI's signal for BIIB is Strong ↑; the stock is at $209.78 (-0.41% today); neutral (RSI 55); technical trend is Raise; news sentiment is positive.
Data as of Aug 14 2026, 1:04 PM. Informational analytics only — not investment advice.
| AI signal (Strength) | Strong ↑ |
|---|---|
| Price | $209.78 |
| Change today | -0.41% |
| RSI (14) | 55.22 |
| Relative volume | 0.23 |
| Composite (RMTPGV) score | 🔒 members |
| Market cap | $31.0B |
| Forward P/E | 12.64 |
| 52-week high | -4.5% away |
| 52-week low | +59.5% above |
| Technical trend | RAISE-2024-01-26 |
| News sentiment | Positive |
| Sector | Healthcare-Pharma |
| Next earnings | 7/29/2026 8:30:00 AM |
As of Aug 14 2026, 1:04 PM, AkshayaAI assigns BIIB (Biogen Inc) a Strong signal. The composite (RMTPGV) score and full factor breakdown are available to signed-in members.
BIIB's RSI is neutral (RSI 55). A reading above 70 is typically considered overbought and below 30 oversold.
BIIB is trading about 5% below its 52-week high and 59% above its 52-week low as of Aug 14 2026, 1:04 PM.
BIIB's next earnings date is 7/29/2026 8:30:00 AM.
BIIB is classified under Healthcare-Pharma in AkshayaAI's taxonomy.
AkshayaAI provides AI-generated, informational stock analytics for US and India markets. This is not personalized investment advice. Figures are as of Aug 14 2026, 1:04 PM and may not reflect real-time prices. Always do your own research.
Instant, data-backed answers — free to try.